Hou C, Jiang ZZ, Pan B, et al. - The therapeutic efficacy and clinical safety of the combination therapy of apatinib plus chemotherapy vs chemotherapy alone were investigated in patients with refractory or recurrent ovarian carcinoma (OC).

• Searching Chinese and English databases, researchers identified 15 eligible studies [randomized controlled trials or case-control studies] covering 1,020 patients for inclusion in this review and meta-analysis.

• Findings suggest retrieval of better clinical benefits for OC in correlation with providing combination treatment of apatinib plus chemotherapy vs chemotherapy alone.

• Hence, suitable patients with OC should be administered combination treatment after the failure of standard regimens.